A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

Benoit Callendret, Jort Vellinga, Kerstin Wunderlich, Ariane Rodriguez, Robin Steigerwald, Ulrike Dirmeier, Cedric Cheminay, Ariane Volkmann, Trevor Brasel, Ricardo Carrion, Luis D. Giavedoni, Jean L. Patterson, Chad Mire, Thomas Geisbert, Jay W. Hooper, Mo Weijtens, Jutta Hartkoorn-Pasma, Jerome Custers, Maria Grazia Pau, Hanneke Schuitemaker & 1 others Roland Zahn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.

Original languageEnglish (US)
Article numbere0192312
JournalPLoS One
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Marburgvirus
Filoviridae
Ebolavirus
Viruses
Primates
Vaccines
glycoproteins
Glycoproteins
vaccines
Marburg virus
Infection
infection
Sudan Ebola virus
viruses
immune response
Vaccinia virus
Vaccination
vaccination
Sudan
Adenoviridae

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. / Callendret, Benoit; Vellinga, Jort; Wunderlich, Kerstin; Rodriguez, Ariane; Steigerwald, Robin; Dirmeier, Ulrike; Cheminay, Cedric; Volkmann, Ariane; Brasel, Trevor; Carrion, Ricardo; Giavedoni, Luis D.; Patterson, Jean L.; Mire, Chad; Geisbert, Thomas; Hooper, Jay W.; Weijtens, Mo; Hartkoorn-Pasma, Jutta; Custers, Jerome; Pau, Maria Grazia; Schuitemaker, Hanneke; Zahn, Roland.

In: PLoS One, Vol. 13, No. 2, e0192312, 01.02.2018.

Research output: Contribution to journalArticle

Callendret, B, Vellinga, J, Wunderlich, K, Rodriguez, A, Steigerwald, R, Dirmeier, U, Cheminay, C, Volkmann, A, Brasel, T, Carrion, R, Giavedoni, LD, Patterson, JL, Mire, C, Geisbert, T, Hooper, JW, Weijtens, M, Hartkoorn-Pasma, J, Custers, J, Pau, MG, Schuitemaker, H & Zahn, R 2018, 'A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates' PLoS One, vol. 13, no. 2, e0192312. https://doi.org/10.1371/journal.pone.0192312
Callendret, Benoit ; Vellinga, Jort ; Wunderlich, Kerstin ; Rodriguez, Ariane ; Steigerwald, Robin ; Dirmeier, Ulrike ; Cheminay, Cedric ; Volkmann, Ariane ; Brasel, Trevor ; Carrion, Ricardo ; Giavedoni, Luis D. ; Patterson, Jean L. ; Mire, Chad ; Geisbert, Thomas ; Hooper, Jay W. ; Weijtens, Mo ; Hartkoorn-Pasma, Jutta ; Custers, Jerome ; Pau, Maria Grazia ; Schuitemaker, Hanneke ; Zahn, Roland. / A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. In: PLoS One. 2018 ; Vol. 13, No. 2.
@article{edc29b74541f49cb9d3d1bcd2f3f0ee6,
title = "A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates",
abstract = "The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Ta{\"i} Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75{\%}-100{\%} protection) and EBOV (range 50{\%} to 100{\%}) challenge, and partial protection (75{\%}) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.",
author = "Benoit Callendret and Jort Vellinga and Kerstin Wunderlich and Ariane Rodriguez and Robin Steigerwald and Ulrike Dirmeier and Cedric Cheminay and Ariane Volkmann and Trevor Brasel and Ricardo Carrion and Giavedoni, {Luis D.} and Patterson, {Jean L.} and Chad Mire and Thomas Geisbert and Hooper, {Jay W.} and Mo Weijtens and Jutta Hartkoorn-Pasma and Jerome Custers and Pau, {Maria Grazia} and Hanneke Schuitemaker and Roland Zahn",
year = "2018",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0192312",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

AU - Callendret, Benoit

AU - Vellinga, Jort

AU - Wunderlich, Kerstin

AU - Rodriguez, Ariane

AU - Steigerwald, Robin

AU - Dirmeier, Ulrike

AU - Cheminay, Cedric

AU - Volkmann, Ariane

AU - Brasel, Trevor

AU - Carrion, Ricardo

AU - Giavedoni, Luis D.

AU - Patterson, Jean L.

AU - Mire, Chad

AU - Geisbert, Thomas

AU - Hooper, Jay W.

AU - Weijtens, Mo

AU - Hartkoorn-Pasma, Jutta

AU - Custers, Jerome

AU - Pau, Maria Grazia

AU - Schuitemaker, Hanneke

AU - Zahn, Roland

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.

AB - The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.

UR - http://www.scopus.com/inward/record.url?scp=85042455926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042455926&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0192312

DO - 10.1371/journal.pone.0192312

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0192312

ER -